Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KRAS | P01116 | 20/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.38 |
| ▸ | CYP3A5 | P20815 | 1/20 | 0.38 |
| ▸ | CYP3A7 | P24462 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | CYP3A43 | Q9HB55 | 1/20 | 0.38 |
| ▸ | SOS1 | Q07889 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27138408 | 0.88 | KRAS (0.44) | KRASCYP3A4CYP2D6CYP3A5CYP3A7 | |
| SCHEMBL30996224 | 0.86 | KRAS (0.53) | KRASCYP3A4CYP2D6CYP3A5CYP3A7 | |
| SCHEMBL27139506 | 0.86 | KRAS (0.53) | KRASCYP3A4CYP2D6CYP3A5CYP3A7 | |
| SCHEMBL29907640 | 0.85 | KRAS (0.42) | KRASCYP3A4CYP2D6CYP3A5CYP3A7 | |
| SCHEMBL29907445 | 0.84 | KRAS (0.45) | KRASSOS1 | |
| SCHEMBL27218583 | 0.84 | KRAS (0.45) | KRASSOS1 | |
| SCHEMBL30725816 | 0.84 | KRAS (0.45) | KRASSOS1 | |
| SCHEMBL24692997 | 0.83 | KRAS (0.60) | KRAS | |
| SCHEMBL29828781 | 0.81 | KRAS (0.48) | KRAS | |
| SCHEMBL27218572 | 0.81 | KRAS (0.48) | KRAS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4053118-B1 | SUBSTITUTED HETEROCYCLIC FUSED CYCLIC COMPOUND, PREPARATION METHOD THEREFOR AND PHARMACEUTICAL USE THEREOF | GENFLEET THERAPEUTICS SHANGHAI INC (CN) | 2024-10-09 | — | — | EP | disclosed |
| US-12054497-B2 | Substituted heterocyclic fused cyclic compound, preparation method therefor and pharmaceutical use thereof | Genfleet Therapeutics (Shanghai)Inc. (CN) | 2024-08-06 | — | — | US | disclosed |
| US-20240158417-A1 | SUBSTITUTED HETEROCYCLIC FUSED CYCLIC COMPOUND, PREPARATION METHOD THEREFOR AND PHARMACEUTICAL USE THEREOF | GENFLEET THERAPEUTICS (SHANGHAI) INC. (CN) | 2024-05-16 | — | — | US | disclosed |
| EP-4328229-A2 | SUBSTITUTED HETEROCYCLIC FUSED CYCLIC COMPOUND, PREPARATION METHOD THEREFOR AND PHARMACEUTICAL USE THEREOF | Genfleet Therapeutics (Shanghai) Inc. (CN) | 2024-02-28 | — | — | EP | disclosed |
| US-20230084095-A1 | SUBSTITUTED HETEROCYCLIC FUSED CYCLIC COMPOUND, PREPARATION METHOD THEREFOR AND PHARMACEUTICAL USE THEREOF | GENFLEET THERAPEUTICS (SHANGHAI) INC. (CN) | 2023-03-16 | — | — | US | disclosed |
| EP-4053118-A1 | SUBSTITUTED HETEROCYCLIC FUSED CYCLIC COMPOUND, PREPARATION METHOD THEREFOR AND PHARMACEUTICAL USE THEREOF | Genfleet Therapeutics (Shanghai) Inc. (CN) | 2022-09-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230084095-A1 | SUBSTITUTED HETEROCYCLIC FUSED CYCLIC COMPOUND, PREPARATION METHOD THEREFOR AND PHARMACEUTICAL USE THEREOF | KRAS, NRAS, HRAS | KRAS 1/4885CYP3A4 305/4885CYP2D6 164/4885 |
| US-20240158417-A1 | SUBSTITUTED HETEROCYCLIC FUSED CYCLIC COMPOUND, PREPARATION METHOD THEREFOR AND PHARMACEUTICAL USE THEREOF | KRAS, NRAS, HRAS | KRAS 1/4885CYP3A4 305/4885CYP2D6 164/4885 |
| US-12054497-B2 | Substituted heterocyclic fused cyclic compound, preparation method therefor and pharmaceutical use thereof | KRAS, NRAS, HRAS | KRAS 1/4885CYP3A4 305/4885CYP2D6 164/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.